ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Roivant Sciences Ltd.
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$34.70+1.17 (+3.49%)
Close on Oct 19, 2026
- Market cap
- $25.01B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
78.1%
564M of 722M shares
Institutional holders
498
100 new, 40 sold out
Net institutional buying
38M
In Q2 2026
Insider trades, 12 months
0 buys · 111 sales
Net sold $869.72M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson | 73,641,253 | 10.30% | 13G (passive) amendment | Feb 27, 2026 |
| FMR LLC | 65,779,464 | 9.50% | 13G (passive) amendment | Dec 31, 2025 |
| SB Investment Advisers (UK) Limited | 62,057,537 | 8.50% | 13G (passive) amendment | Dec 31, 2024 |
| Viking Global Investors LP | 46,013,752 | 6.40% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 41,962,059 | 5.70% | 13G (passive) | Sep 30, 2024 |
| Morgan Stanley | 40,693,386 | 5.70% | 13G (passive) amendment | Jun 30, 2026 |
| SVF Holdings (UK) LLP | 40,315,127 | 5.80% | 13G (passive) amendment | Sep 30, 2025 |
| Ott David C. | 34,237,779 | 5.02% | 13G (passive) amendment | Jun 30, 2025 |
| Dan Oren | 102,849,443 | – | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ROIV | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 81,020,390 | 11.22% | $2.87B | +3,039,137 | 0.12% |
| BlackRock, Inc. | 48,236,091 | 6.68% | $1.71B | +3,981,831 | 0.03% |
| Morgan Stanley | 42,592,905 | 5.90% | $1.51B | −9,235,420 | 0.08% |
| QVT Financial LP | 23,723,074 | 3.28% | $839.56M | −1,438,163 | 50.52% |
| Vanguard Capital Management LLC | 22,123,198 | 3.06% | $782.94M | +1,442,626 | 0.02% |
| Vanguard Portfolio Management LLC | 21,641,339 | 3.00% | $765.89M | +1,802,641 | 0.03% |
| Goldman Sachs Group Inc | 18,556,458 | 2.57% | $656.71M | +7,444,867 | 0.06% |
| State Street Corp | 17,795,975 | 2.46% | $629.80M | +1,609,362 | 0.02% |
| UBS Group AG | 17,466,641 | 2.42% | $618.14M | −5,152,831 | 0.08% |
| Assenagon Asset Management S.A. | 16,725,904 | 2.32% | $591.93M | +9,649,416 | 0.37% |
| Farallon Capital Management LLC | 14,309,000 | 1.98% | $506.40M | +4,634,000 | 2.34% |
| Geode Capital Management, LLC | 11,674,380 | 1.62% | $425.54M | +1,491,903 | 0.02% |
| Adage Capital Partners Gp, L.L.C. | 10,349,328 | 1.43% | $366.26M | −2,444,769 | 0.51% |
| Two Seas Capital LP | 8,475,356 | 1.17% | $299.94M | −852,935 | 5.94% |
| Perceptive Advisors LLC | 8,085,461 | 1.12% | $286.14M | −200,000 | 4.30% |
| Patient Square Capital LP | 8,020,928 | 1.11% | $283.86M | −145,119 | 43.97% |
| Invesco Ltd. | 7,531,192 | 1.04% | $266.53M | +1,092,047 | 0.02% |
| Darwin Global Management, Ltd. | 6,747,300 | 0.93% | $234.33M | −50,000 | 6.23% |
| Aqr Capital Management LLC | 6,633,560 | 0.92% | $234.03M | +686,702 | 0.08% |
| Viking Global Investors LP | 6,271,467 | 0.87% | $221.95M | −380,981 | 0.63% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 498 | 564M | 78.1% | 100 / 202 | 141 / 40 | 83M | 45M |
| Q1 2026 | 444 | 531M | 73.5% | 97 / 174 | 121 / 47 | 125M | 62M |
| Q4 2025 | 400 | 509M | 70.5% | 110 / 150 | 94 / 40 | 106M | 98M |
| Q3 2025 | 338 | 503M | 69.6% | 59 / 124 | 96 / 56 | 50M | 63M |
| Q2 2025 | 338 | 516M | 71.5% | 61 / 115 | 110 / 35 | 53M | 95M |
| Q1 2025 | 313 | 558M | 77.2% | 57 / 91 | 107 / 59 | 27M | 29M |
| Q4 2024 | 319 | 563M | 77.9% | 69 / 93 | 104 / 41 | 31M | 40M |
| Q3 2024 | 294 | 572M | 79.2% | 54 / 122 | 69 / 52 | 109M | 47M |
| Q2 2024 | 294 | 547M | 75.7% | 64 / 102 | 83 / 26 | 55M | 111M |
| Q1 2024 | 259 | 604M | 83.6% | 69 / 92 | 63 / 34 | 139M | 99M |
| Q4 2023 | 225 | 564M | 78.1% | 61 / 86 | 52 / 41 | 84M | 65M |
| Q3 2023 | 206 | 546M | 75.6% | 53 / 88 | 47 / 27 | 88M | 40M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ROIV | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 15,987,737 | 2.21% | $565.81M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 11,546,280 | 1.60% | $408.62M | 0.22% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 6,658,616 | 0.92% | $235.65M | 0.50% | Jun 30, 2026 |
| Invesco S&P MidCap Momentum ETF | 5,219,192 | 0.72% | $176.98M | 2.47% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 5,168,626 | 0.72% | $182.92M | 0.19% | Jun 30, 2026 |
| Vanguard Explorer Fund | 2,969,485 | 0.41% | $100.70M | 0.46% | Jul 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 1,165,423 | 0.16% | $39.52M | 0.08% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 1,128,232 | 0.16% | $33.84M | 0.18% | May 31, 2026 |
| iShares Russell 1000 Value ETF | 1,093,652 | 0.15% | $38.70M | 0.05% | Jun 30, 2026 |
| Vanguard S&p Mid-Cap 400 Index Fund | 719,473 | 0.10% | $21.58M | 0.39% | May 31, 2026 |
| Invesco BuyBack AchieversTM ETF | 582,864 | 0.08% | $19.76M | 0.87% | Jul 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 519,187 | 0.07% | $18.37M | 0.01% | Jun 30, 2026 |
| Bridge Builder Large Cap Growth Fund | 505,669 | 0.07% | $17.90M | 0.06% | Jun 30, 2026 |
| Vanguard Total World Stock Index Fund | 416,293 | 0.06% | $14.12M | 0.01% | Jul 31, 2026 |
| Nuveen Equity Index Fund | 380,966 | 0.05% | $12.92M | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mayukh Sukhatme | President & CIO, Director | 20,433,193 | 2.83% | Aug 21, 2026 |
| Matthew Gline | CEO, Director | 16,659,945 | 2.31% | Jul 2, 2026 |
| Richard Pulik | CFO | 269,681 | 0.04% | Sep 22, 2026 |
| Jennifer Humes | Chief Accounting Officer | 106,419 | 0.01% | Sep 22, 2026 |
| Eric Venker | President & Immunovant CEO | 1,599,154 | 0.22% | Sep 1, 2026 |
| Frank Torti | President and Vant Chair | 13,536,202 | 1.87% | Jul 2, 2026 |
| Rakhi Kumar | Chief Accounting Officer | 162,306 | 0.02% | Feb 24, 2025 |
| James C. Momtazee | Director | 111,959 | 0.02% | Sep 18, 2026 |
| Keith S. Manchester | Director | 15,442,623 | 2.14% | Sep 18, 2026 |
| Meghan Fitzgerald | Director | 41,162 | 0.01% | Sep 18, 2026 |
| Ilan Oren | Director | 123,680 | 0.02% | Sep 18, 2026 |
| Daniel Allen Gold | Director | 22,654,981 | 3.14% | Sep 18, 2026 |
| Epperly Melissa B, | Director | 14,954 | 0.00% | Sep 18, 2026 |
| Financial LP QVT | – | 13,689,166 | 1.90% | Jun 30, 2026 |
| Vivek Ramaswamy | 10% owner | 47,490,320 | 6.57% | Dec 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jennifer Humes Chief Accounting Officer | Sep 20, 2026 | Tax withholding | −3,880 | $39.77 | $154.31K | 106,419 |
| Richard Pulik CFO | Sep 20, 2026 | Tax withholding | −2,129 | $39.77 | $84.67K | 269,681 |
| Meghan Fitzgerald Director | Sep 16, 2026 | Award | +5,054 | – | – | 41,162 |
| Keith S. Manchester Director | Sep 16, 2026 | Award | +5,054 | – | – | 1,753,457 |
| James C. Momtazee Director | Sep 16, 2026 | Award | +5,054 | – | – | 111,959 |
| Daniel Allen Gold Director | Sep 16, 2026 | Award | +5,054 | – | – | 8,965,815 |
| Ilan Oren Director | Sep 16, 2026 | Award | +5,054 | – | – | 123,680 |
| Epperly Melissa B, Director | Sep 16, 2026 | Award | +5,054 | – | – | 14,954 |
| Epperly Melissa B, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −600 | $40.38 | $24.23K | 9,900 |
| Epperly Melissa B, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −4,338 | $39.65 | $172.00K | 10,500 |
| Meghan Fitzgerald Director | Sep 15, 2026 | Sale(10b5-1 plan) | −4,712 | $39.68 | $186.97K | 36,508 |
| Meghan Fitzgerald Director | Sep 15, 2026 | Sale(10b5-1 plan) | −400 | $40.45 | $16.18K | 36,108 |
| Daniel Allen Gold Director | Sep 10, 2026 | Tax withholding | −5,133 | $40.94 | $210.15K | 8,960,761 |
| Epperly Melissa B, Director | Sep 10, 2026 | Tax withholding | −2,179 | $40.94 | $89.21K | 14,838 |
| Ilan Oren Director | Sep 10, 2026 | Tax withholding | −2,378 | $40.94 | $97.36K | 118,626 |
| Meghan Fitzgerald Director | Sep 10, 2026 | Tax withholding | −1,743 | $40.94 | $71.36K | 41,220 |
| James C. Momtazee Director | Sep 10, 2026 | Tax withholding | −2,905 | $40.94 | $118.93K | 106,905 |
| Meghan Fitzgerald Director | Sep 8, 2026 | Option exercise | +20,000 | $8.80 | $176.00K | 62,963 |
| Meghan Fitzgerald Director | Sep 8, 2026 | Sale(10b5-1 plan) | −20,000 | $39.90 | $798.00K | 42,963 |
| Eric Venker President & Immunovant CEO | Aug 28, 2026 | Sale(10b5-1 plan) | −33,818 | $36.44 | $1.23M | 1,599,154 |
| Eric Venker President & Immunovant CEO | Aug 28, 2026 | Option exercise | +200,000 | $3.85 | $770.00K | 1,799,154 |
| Eric Venker President & Immunovant CEO | Aug 28, 2026 | Sale(10b5-1 plan) | −166,182 | $35.63 | $5.92M | 1,632,972 |
| Mayukh Sukhatme President & CIO, Director | Aug 21, 2026 | Option exercise | +144,756 | $3.85 | $557.31K | 18,775,495 |
| Mayukh Sukhatme President & CIO, Director | Aug 21, 2026 | Sale | −144,756 | $36.48 | $5.28M | 18,630,739 |
| Richard Pulik CFO | Aug 20, 2026 | Tax withholding | −5,749 | $36.84 | $211.79K | 271,810 |
| Eric Venker President & Immunovant CEO | Aug 20, 2026 | Tax withholding | −13,909 | $36.84 | $512.41K | 1,599,154 |
| Mayukh Sukhatme President & CIO, Director | Aug 20, 2026 | Option exercise | +17,519 | $3.85 | $67.45K | 18,648,258 |
| Mayukh Sukhatme President & CIO, Director | Aug 20, 2026 | Sale | −17,519 | $37.30 | $653.46K | 18,630,739 |
| Mayukh Sukhatme President & CIO, Director | Aug 19, 2026 | Option exercise | +172,899 | $3.85 | $665.66K | 18,803,638 |
| Mayukh Sukhatme President & CIO, Director | Aug 19, 2026 | Sale | −172,899 | $37.17 | $6.43M | 18,630,739 |
| Mayukh Sukhatme President & CIO, Director | Aug 18, 2026 | Sale | −31,801 | $37.18 | $1.18M | 18,630,739 |
| Mayukh Sukhatme President & CIO, Director | Aug 18, 2026 | Option exercise | +31,801 | $3.85 | $122.43K | 18,662,540 |
| Mayukh Sukhatme President & CIO, Director | Aug 18, 2026 | Sale | −105,141 | $36.59 | $3.85M | 18,630,739 |
| Mayukh Sukhatme President & CIO, Director | Aug 18, 2026 | Option exercise | +105,141 | $3.85 | $404.79K | 18,735,880 |
| Mayukh Sukhatme President & CIO, Director | Aug 17, 2026 | Sale | −284,707 | $36.25 | $10.32M | 18,630,739 |
| Mayukh Sukhatme President & CIO, Director | Aug 17, 2026 | Option exercise | +284,707 | $3.85 | $1.10M | 18,915,446 |
| Mayukh Sukhatme President & CIO, Director | Aug 14, 2026 | Option exercise | +243,177 | $3.85 | $936.23K | 18,873,916 |
| Mayukh Sukhatme President & CIO, Director | Aug 14, 2026 | Sale | −243,177 | $36.23 | $8.81M | 18,630,739 |
| Eric Venker President & Immunovant CEO | Jul 27, 2026 | Option exercise | +200,000 | $3.85 | $770.00K | 1,813,063 |
| Eric Venker President & Immunovant CEO | Jul 27, 2026 | Sale(10b5-1 plan) | −200,000 | $34.95 | $6.99M | 1,613,063 |
| Epperly Melissa B, Director | Jul 17, 2026 | Award | +543 | – | – | 17,017 |
| Ilan Oren Director | Jul 17, 2026 | Award | +775 | – | – | 121,004 |
| James C. Momtazee Director | Jul 17, 2026 | Award | +405 | – | – | 109,810 |
| Mayukh Sukhatme President & CIO, Director | Jun 30, 2026 | Tax withholding | −46,878 | $35.39 | $1.66M | 18,630,739 |
| Meghan Fitzgerald Director | Jun 30, 2026 | Sale(10b5-1 plan) | −10,000 | $34.90 | $349.00K | 42,963 |
| Meghan Fitzgerald Director | Jun 30, 2026 | Option exercise | +10,000 | $8.80 | $88.00K | 52,963 |
| Matthew Gline CEO, Director | Jun 30, 2026 | Tax withholding | −76,171 | $35.39 | $2.70M | 16,659,945 |
| Frank Torti President and Vant Chair | Jun 30, 2026 | Tax withholding | −40,310 | $35.39 | $1.43M | 13,536,202 |
| Daniel Allen Gold Director | Jun 30, 2026 | Sale | −12,380 | $35.28 | $436.77K | 13,689,166 |
| Keith S. Manchester Director | Jun 30, 2026 | Sale | −12,380 | $35.28 | $436.77K | 13,689,166 |
| Keith S. Manchester Director | Jun 30, 2026 | Sale | −200,000 | $35.45 | $7.09M | 1,748,403 |
| Financial LP QVT – | Jun 30, 2026 | Sale | −12,380 | $35.28 | $436.77K | 13,689,166 |
| Epperly Melissa B, Director | Jun 29, 2026 | Sale(10b5-1 plan) | −15,002 | $34.32 | $514.87K | 19,222 |
| Epperly Melissa B, Director | Jun 29, 2026 | Sale(10b5-1 plan) | −2,748 | $34.71 | $95.38K | 16,474 |
| Epperly Melissa B, Director | Jun 29, 2026 | Option exercise | +17,750 | $4.46 | $79.17K | 34,224 |
| Daniel Allen Gold Director | Jun 29, 2026 | Sale | −600,000 | $34.59 | $20.75M | 13,701,546 |
| Daniel Allen Gold Director | Jun 29, 2026 | Sale | −200,000 | $34.44 | $6.89M | 14,301,546 |
| Keith S. Manchester Director | Jun 29, 2026 | Sale | −200,000 | $34.44 | $6.89M | 14,301,546 |
| Keith S. Manchester Director | Jun 29, 2026 | Sale | −600,000 | $34.59 | $20.75M | 13,701,546 |
| Financial LP QVT – | Jun 29, 2026 | Sale | −200,000 | $34.44 | $6.89M | 14,301,546 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Eric Venker Officer | Sep 30, 2026 | 200,000 | $7.32M | Sep 30, 2026 | Options Exercise - Grant Date 04/20/2022 |
| Epperly Melissa Director | Sep 15, 2026 | 22,688 | $930.66K | Sep 15, 2026 | Exercise of Stock Options |
| Fitzgerald Meghan Officer | Sep 15, 2026 | 5,112 | $209.69K | Sep 15, 2026 | Restricted Stock Units |
| Fitzgerald Meghan Director | Sep 8, 2026 | 20,000 | $698.60K | Sep 8, 2026 | Exercise of Stock Options |
| Eric Venker Officer | Aug 28, 2026 | 200,000 | $7.15M | Aug 28, 2026 | Options Exercise - Grant Date 04/20/2022 |
| Sukhatme Mayukh Officer, Director | Aug 21, 2026 | 144,756 | $5.28M | Aug 21, 2026 | Exercise of Options Under a Registered Plan |
| Sukhatme Mayukh Officer, Director | Aug 20, 2026 | 17,519 | $653.41K | Aug 20, 2026 | Exercise of Options Under a Registered Plan |
| Sukhatme Mayukh Officer, Director | Aug 19, 2026 | 172,899 | $6.43M | Aug 19, 2026 | Exercise of Options Under a Registered Plan |
| Sukhatme Mayukh Officer, Director | Aug 18, 2026 | 136,942 | $5.03M | Aug 18, 2026 | Exercise of Options Under a Registered Plan |
| Sukhatme Mayukh Officer, Director | Aug 17, 2026 | 284,707 | $10.32M | Aug 17, 2026 | Exercise of Options Under a Registered Plan |
| Sukhatme Mayukh Officer, Director | Aug 14, 2026 | 243,177 | $8.81M | Aug 14, 2026 | Exercise of Options Under a Registered Plan |
| Eric Venker Officer | Jul 27, 2026 | 200,000 | $6.99M | Jul 27, 2026 | Options Exercise - Grant Date 04/20/2022 |
| Fitzgerald Meghan Director | Jun 30, 2026 | 10,000 | $347.30K | Jun 30, 2026 | Exercise of Stock Options |
| S. Manchester Keith Director | Jun 30, 2026 | 200,000 | $7.09M | Jun 30, 2026 | Founder Stock |
| Epperly Melissa Director | Jun 29, 2026 | 17,750 | $604.74K | Jun 29, 2026 | Exercise of Stock Options |